BLUEBIRD BIO (UK) LTD.

• ⚠

  Material uncertainty over going concern

  The financial statements for the year ended 31 December 2024 have been prepared on a basis other than that of a going concern reflecting the decision to cease activities in early 2026. This includes the cessation of activity by the Company and its European subsidiaries. The director has also confirmed that the parent company, Genetix Biopharmaceuticals Inc. (formerly Bluebird Bio, Inc.) has committed to make funds available to the Company to enable it to meet its liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements and therefore there has not been any adjustment to intercompany balances.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Bishop Fleming Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The financial statements for the year ended 31 December 2024 have been prepared on a basis other than that of a going concern reflecting the decision to cease activities in early 2026. This includes the cessation of activity by the Company and its European subsidiaries. The director has also confirmed that the parent company, Genetix Biopharmaceuticals Inc. (formerly Bluebird Bio, Inc.) has committed to make funds available to the Company to enable it to meet its liabilities as they fall due for a period of at least 12 months from the date of approval of these financial statements and therefore there has not been any adjustment to intercompany balances.”

Group structure

1. BLUEBIRD BIO (UK) LTD. · parent
   1. Bluebird Bio (Switzerland) GmbH 100% · Switzerland · European headquarters
   2. Bluebird Bio (Germany) GmbH i.L. 100% · Germany · Medical, commercial and regulatory affairs
   3. Bluebird Bio (Netherlands) B.V. 100% · Netherlands · Medical, commercial and regulatory affairs

Significant events

• “In August 2021, the Bluebird Bio Group made the decision to cease activities in Europe by early 2026. This includes the cessation of activity by the Company and its European subsidiaries. The cessation of activities is still ongoing with subsidiaries in France and Italy already closed and the Germany, Netherlands and Switzerland subsidiaries close to closure. The distribution expected to receive from the remaining subsidiaries on cessation amounts to £1,642,972.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

2

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +136%

  £5,691 → £13,432

• Cash

  +161.8%

  £11,350 → £29,717

• Net assets

  -0.8%

  £3,945,280 → £3,911,917

• Employees

  0%

  1 → 1

• Operating profit

  -156.3%

  £1,440 → -£810

• Profit before tax

  +830,180.6%

  -£36 → £298,829

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers